Shanghai Haohai Biological Technology Co., Ltd. (HAOHAI BIOTEC) disclosed a further on-market repurchase of 12,000 H shares on 25 August 2026. The shares were bought at prices ranging from HKD 16.30 to HKD 16.49, for an aggregate consideration of HKD 0.20 million. All repurchased shares are intended for cancellation.

Including this latest transaction, a total of 495,600 H shares have been repurchased under the buyback mandate approved on 29 May 2026, representing 1.42% of the company’s issued share capital as at the mandate date. The mandate allows for the repurchase of up to 3,478,034 shares.

Issued-share structure as at 25 August 2026: • H shares in issue (excluding shares pending cancellation): 34.78 million • A shares in issue: 190.20 million • Treasury A shares: 3.85 million • Combined issued shares (including treasury): 224.98 million

Repurchased H shares pending cancellation now stand at 495,600, acquired at volume-weighted average prices of HKD 16.40 on 20 July, HKD 16.79 on 21 July, HKD 15.78 on 24 August, and HKD 16.35 on 25 August.

No new shares may be issued, nor treasury shares transferred, until 24 September 2026 in accordance with Hong Kong Listing Rule 10.06(3)(a).